Cargando…
Cortical porosity is elevated after a single dose of zoledronate in two rodent models of chronic kidney disease
PURPOSE: Patients with chronic kidney disease (CKD) have high risk of fracture in part due to cortical bone deterioration. The goal of this study was to assess the impact of two different bisphosphonates and dosing regimens on cortical microstructure (porosity, thickness, area) and bone mechanical p...
Autores principales: | Swallow, Elizabeth A., Metzger, Corinne E., Chen, Neal X., Wallace, Joseph M., Tippen, Samantha P., Kohler, Rachel, Moe, Sharon M., Allen, Matthew R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891946/ https://www.ncbi.nlm.nih.gov/pubmed/35252482 http://dx.doi.org/10.1016/j.bonr.2022.101174 |
Ejemplares similares
-
Cortical porosity occurs at varying degrees throughout the skeleton in rats with chronic kidney disease
por: Metzger, Corinne E., et al.
Publicado: (2022) -
Tracking changes of individual cortical pores over 1 year via HR-pQCT in a small cohort of 60-year-old females
por: Surowiec, Rachel K., et al.
Publicado: (2022) -
Denosumab versus zoledronate for the treatment of low bone mineral density in male HIV-infected patients
por: Makras, Polyzois, et al.
Publicado: (2021) -
Intravenous Zoledronate 4 mg for the treatment of post-menopausal osteoporosis: A prospective open-labeled study
por: Arunthanachaikul, Thunyawarin, et al.
Publicado: (2021) -
Investigating the gut-brain axis in a neurodevelopmental rodent model of schizophrenia
por: Katz-Barber, Max W., et al.
Publicado: (2020)